Search research articles
Contact Us
Filters
Showing results (181-190 of 251) with videos related to
Page
of 26
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 16, 2004
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer
E Van Cutsem, H van de Velde, P Karasek, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 22, 2016
Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer
T R J Evans, E Van Cutsem, M J Moore, et al.
Critical Reviews in Oncology/Hematology
|
February 11, 2015
Pooled analysis of the surgical treatment for colorectal cancer liver metastases
G Veereman, J Robays, L Verleye, et al.
British Journal of Cancer
|
May 10, 2012
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells
T Troiani, L Vecchione, E Martinelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 17, 2014
Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial
E Élez, I Kocáková, T Höhler, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 5, 2020
Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study
E Van Cutsem, K Muro, D Cunningham, et al.
Acta Gastro-Enterologica Belgica
|
November 23, 2011
Familial adenomatous polyposis: clinical presentation, detection and surveillance
S Laurent, D Franchimont, J P Coppens, et al.
ESMO Open
|
December 20, 2023
Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study
J Ajani, F El Hajbi, D Cunningham, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 22, 2002
Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival
T Conroy, P L Etienne, A Adenis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 31, 2012
Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer
M M Eatock, N C Tebbutt, C L Bampton, et al.
Page
of 26
Search research articles
Search
Showing results (181-190 of 251) with videos related to
Sort By:
Page
of 26
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 16, 2004
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer
E Van Cutsem, H van de Velde, P Karasek, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 22, 2016
Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer
T R J Evans, E Van Cutsem, M J Moore, et al.
Critical Reviews in Oncology/Hematology
|
February 11, 2015
Pooled analysis of the surgical treatment for colorectal cancer liver metastases
G Veereman, J Robays, L Verleye, et al.
British Journal of Cancer
|
May 10, 2012
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells
T Troiani, L Vecchione, E Martinelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 17, 2014
Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial
E Élez, I Kocáková, T Höhler, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 5, 2020
Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study
E Van Cutsem, K Muro, D Cunningham, et al.
Acta Gastro-Enterologica Belgica
|
November 23, 2011
Familial adenomatous polyposis: clinical presentation, detection and surveillance
S Laurent, D Franchimont, J P Coppens, et al.
ESMO Open
|
December 20, 2023
Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study
J Ajani, F El Hajbi, D Cunningham, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 22, 2002
Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival
T Conroy, P L Etienne, A Adenis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 31, 2012
Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer
M M Eatock, N C Tebbutt, C L Bampton, et al.
Page
of 26